Related Articles
Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer
HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma
Identification of a novel HLA-A*02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene
Prostate-specific antigen-reactive cytotoxic T lymphocyte precursors in colon cancer patients
Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer